精品人妻无码一区二区三区软件 ,麻豆亚洲AV成人无码久久精品,成人欧美一区二区三区视频,免费av毛片不卡无码

您現(xiàn)在的位置是:首頁SCI期刊MedChemComm
MedChemComm

MedChemComm SCIE

2040-2503

醫(yī)學(xué)

No

MEDCHEMCOMM

2010

225

ENGLAND

http://pubs.rsc.org/en/journals/journalissues/md

一般,3-8周審稿時間

2.394影響因子

生化與分子生物學(xué)小學(xué)科

SCI三劍客

中文簡介

醫(yī)學(xué)化學(xué)通訊歡迎在藥物化學(xué)和相關(guān)藥物發(fā)現(xiàn)科學(xué)方面的重要研究和評論文章。我們接受通訊和全紙風(fēng)格的文章。在醫(yī)學(xué)化學(xué)通訊上發(fā)表的研究論文必須比以前發(fā)表的論文有顯著的進步,或者帶來新的想法或結(jié)果,這些想法或結(jié)果可能會對他們的領(lǐng)域產(chǎn)生強大的影響。期刊范圍內(nèi)的領(lǐng)域包括:新型化學(xué)或生化實體的設(shè)計、合成和生物評價。為了適合發(fā)表,這些必須表現(xiàn)出顯著的潛力,作為新的藥物制劑,工具,探針或潛在的藥物。對已知化學(xué)或生物化學(xué)實體的修改,可使對它們的結(jié)構(gòu)-活性關(guān)系有更大的了解,改善它們的性質(zhì)或提供其他有重要價值的信息,例如,為已知的試劑確定新目標。常規(guī)的修改很少或沒有改進,不適合醫(yī)學(xué)通訊。注意,只有在明確的陽性對照和陰性對照的情況下進行新化合物或現(xiàn)有化合物作為藥理學(xué)試劑進行測試的研究,并在原稿中參考現(xiàn)有最有效的藥劑,才會考慮這些研究。這種類型的研究應(yīng)該包括一個明確定義和假設(shè)驅(qū)動的復(fù)合設(shè)計理論。潛在的抗菌藥物應(yīng)進行細胞毒性和對非相關(guān)病原體的活性測試。在更廣泛的化學(xué)和生物科學(xué)(例如,使合成化學(xué),化學(xué)生物學(xué),組學(xué)科學(xué),結(jié)構(gòu)生物學(xué),納米科學(xué))的新方法和技術(shù)應(yīng)用于藥物發(fā)現(xiàn)。計算研究是受歡迎的,因為它們大大提高了藥物化學(xué)知識。使用已建立的計算方法進行的研究應(yīng)包括原始預(yù)測,并應(yīng)附以新的實驗數(shù)據(jù),以驗證所作的預(yù)測。報道新的計算方法的研究必須通過與實驗數(shù)據(jù)的比較來證明其在藥物化學(xué)中的應(yīng)用。不清楚地將所得結(jié)果與實驗數(shù)據(jù)聯(lián)系起來的計算研究,或者沒有顯示出實用價值的計算研究(或者實用價值不太可能顯著促進該領(lǐng)域的發(fā)展),不適合醫(yī)學(xué)化學(xué)通訊。請注意,沒有實驗數(shù)據(jù)的對接研究不適合發(fā)表在雜志上。研究化合物的分子結(jié)構(gòu)對藥物動力學(xué)行為和藥效學(xué)的影響。請注意,只專注于藥物傳遞劑的研究不適合在醫(yī)學(xué)化學(xué)通訊發(fā)表。為了幫助編輯和審稿人評估每一篇投稿的重要性,我們要求所有投稿作者在投稿時提供一份簡要的重要性陳述。這應(yīng)該包括一句話來總結(jié)手稿中最重要的發(fā)現(xiàn),第二句話來說明為什么這是該領(lǐng)域的重大進展。這一重要性聲明應(yīng)具體側(cè)重于所提交研究報告的重要性,而不是該領(lǐng)域的重要性。

http://mc.manuscriptcentral.com/rsc

英文簡介

MedChemComm welcomes significant research and review articles in medicinal chemistry and related drug discovery science. We accept both communication and full paper style articles.Research articles published in MedChemComm must show a significant advance on previously published work, or bring new thinking or results which will potentially have a strong impact in their field.Examples of areas within the journal's scope are:Design, synthesis and biological evaluation of novel chemical or biochemical entities. To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs.Modifications of known chemical or biochemical entities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or which provide other information of significant value, for example, the identification of a new target for a known agent. Routine modifications with minimal or no improvement are not suitable for MedChemComm.Note that studies where new or existing compounds are tested as pharmacological agents will only be considered if they are carried out in the presence of clear positive and negative controls and reference is made in the manuscript to the most powerful existing agents. Studies of this type should include a clearly defined and hypothesis-driven compound design rationale. Potential antimicrobial agents should be tested for cytotoxicity and activity against non-related pathogens.Novel methodologies and technologies in the broader chemical and biological sciences (for example, enabling synthetic chemistry, chemical biology, -omics sciences, structural biology, nanoscience) with application to drug discovery.Computational studies are welcome where they significantly advance medicinal chemistry knowledge. Studies that use established computational methods should include an original prediction and be accompanied by new experimental data which validates the prediction made. Studies which report novel computational methodology must demonstrate its use in medicinal chemistry through comparison with experimental data. Computational research that does not clearly relate the results obtained to experimental data or which has no demonstrated utility (or where the utility is unlikely to significantly advance the field) is not suitable for MedChemComm. Please note that docking studies presented without experimental data are not suitable for publication in the journal.Studies which examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics.Note that studies which focus solely on drug delivery agents are not suitable for publication in MedChemComm.To help editors and referees assess the significance of each submitted manuscript we ask all authors on submission to provide a brief statement of significance. This should contain one sentence to summarise the most important finding(s) in the manuscript and a second sentence to say why this is a significant advance in the field. This significance statement should focus specifically on the importance of the piece of research being submitted, rather than the importance of the field.

SCI服務(wù)流程
服務(wù)流程
常見問題
Q&A
sci作為國際學(xué)術(shù)界的重要評價指標,對于科研人員的晉升有著不小的幫助。至于, SCI共一作者能晉升副高嗎 ? 能晉升副
副高級和正高級職稱級別對sci論文發(fā)表是有一定要求的,不僅期刊級別有要求,而且對論文的收錄和檢索也是有要求的,
sci一區(qū)都是top期刊嗎? top期刊就是在同類(比如說某工程學(xué)、某自然資源類,水文學(xué)類、醫(yī)藥類等)期刊中的排名。沒有明確
在醫(yī)學(xué)領(lǐng)域中的精神病科方向的期刊被SCI所收錄的也不在少數(shù),尤其是非常優(yōu)秀的頂尖期刊,所以這里也是給大家整理了

影響因子趨勢圖

SCI服務(wù)明細

醫(yī)學(xué)方向的SCI期刊推薦
R&J
大類學(xué)科同領(lǐng)域優(yōu)質(zhì)期刊 大類學(xué)科 小類學(xué)科 影響因子 分區(qū) ISSN
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 醫(yī)學(xué) 生化與分子生物學(xué) 6.887 N/A 0304-419X
BIOORGANIC & MEDICINAL CHEMISTRY 醫(yī)學(xué) 生化與分子生物學(xué) 2.802 3區(qū) 0968-0896
Chemical Biology & Drug Design 醫(yī)學(xué) 生化與分子生物學(xué) 2.256 4區(qū) 1747-0277
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY 醫(yī)學(xué) 生化與分子生物學(xué) 2.697 N/A 1532-0456
CURRENT DRUG METABOLISM 醫(yī)學(xué) 生化與分子生物學(xué) 2.277 3區(qū) 1389-2002
INFECT MED 醫(yī)學(xué) 生化與分子生物學(xué) N/A 3區(qū) 0929-8673
MED ORAL PATOL ORAL 醫(yī)學(xué) 生化與分子生物學(xué) N/A N/A 0957-9672
CURRENT PHARMACEUTICAL BIOTECHNOLOGY 醫(yī)學(xué) 生化與分子生物學(xué) 1.516 N/A 1389-2010
CYTOKINE 醫(yī)學(xué) 生化與分子生物學(xué) 3.078 3區(qū) 1043-4666
EXPERIMENTAL AND MOLECULAR MEDICINE 醫(yī)學(xué) 生化與分子生物學(xué) 4.743 2區(qū) 1226-3613
醫(yī)學(xué)領(lǐng)域發(fā)文選擇sci期刊的作者可謂是眾多的,畢竟其有著高價值性和知名度,且也是備受高校和單位認可的。因此不少...
臨床和實驗醫(yī)學(xué)雜志是統(tǒng)計源期刊。 《臨床和實驗醫(yī)學(xué)雜志》是經(jīng)國家科技部和新聞出版總署批準,由北京市衛(wèi)生局主管...
我們都知道sci所收錄的學(xué)科領(lǐng)域在范圍上是較為廣泛的,所以有關(guān)動物醫(yī)學(xué)方向的期刊其也是有不少的。因此最近有作者...
中國生物醫(yī)學(xué)工程學(xué)報不是EI。 《中國生物醫(yī)學(xué)工程學(xué)報》創(chuàng)刊于1982年,雙月刊,是中國生物醫(yī)學(xué)工程學(xué)會主辦的專業(yè)性...
在醫(yī)學(xué)領(lǐng)域,北大核心期刊和科技核心期刊是發(fā)表論文選擇期刊的兩種不同選擇,作者可根據(jù)單位文件要求、研究方向和...
1:CELLULAR AND MOLECULAR LIFE SCIENCES 創(chuàng)刊:1997年 所屬分區(qū):2區(qū) 是否OA:OA期刊 通訊地址:BIRKHAUSER VERLAG AG, VIADUKSTRASSE 40-44, PO B...

發(fā)現(xiàn)心儀選題請?zhí)顔?/b>

獲取發(fā)表周期短、審稿速度快容易錄用的期刊